US firm tests brain implant with patients in China in rare sign of cooperation between both sides
AI-summarised brief · reviewed before publication
A US company, Axoft, has tested a brain implant in four Chinese patients in Shanghai, marking a rare sign of cooperation between the two countries in neurotechnology development. The company has raised $55 million and plans to conduct more clinical trials in China. Axoft's device has been tested in 11 patients, including those in the US and Panama. The brain implant can potentially treat patients with disorders of consciousness and help them communicate via computer.
💡 Why It Matters
- · Brain-computer interfaces have significant potential for medical treatments and industrial applications, making them a key area of competition between the US and China.
- · Axoft's ability to quickly test its device in China highlights the country's advantages in regulatory speed.